Rekod bukti kaedah

Dose-Escalation Design

Dose-Escalation Design, formalized as the Continual Reassessment Method (CRM), is a Bayesian adaptive algorithm for identifying the Maximum Tolerated Dose (MTD) in Phase I clinical trials. Introduced by John O'Quigley, Margaret Pepe, and Lloyd Fisher in 1990, CRM treats dose-toxicity response as a parametric curve, updates a prior probability model after each patient's outcome, and assigns subsequent patients to the dose currently estimated closest to a pre-specified target toxicity probability.

Sources recorded, not reviewed

Rekod sumber

Petikan disalin secara verbatim daripada rekod sumber kaedah. Tiada pengesahan peringkat tuntutan disimpulkan daripadanya.

Dose-Escalation Design (Continual Reassessment Method)

Rekod kaedah taksonomik · process-pipeline / experimental-design

O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. · DOI 10.2307/2531628

Buka kaedah penuh

Tuntutan yang dikurasi

Tuntutan disimpan dalam lejar bukti, setiap satu dengan penilaiannya sendiri.

Tiada tuntutan terkurasi lagi

Pandangan ini tidak mencipta penilaian tuntutan apabila lejar tiada.

Kaedah berkaitan

Dijana daripada graf kaedah dan ditunjukkan sebagai perhubungan yang dicadangkan mesin — tiada tuntutan bukti disimpulkan.